Become a strategic partner for the industrialisation and commercialisation
of this innovation through an operating licence.
PROBALIDY
Probiotic for the prevention of liver disease
Investment: 458k€
Scope: Health
Scientific field(s): Biology and Medicinal Chemistry
Institution(s): Université Paris-Saclay - Inserm - AP-HP
Development: Technology to be marketed
#1
Unique preventive approach to liver disease
#2
Probiotic strains derived from naturally protected patients
#3
Project already highly de-risked scientifically
USE CASES
The PROBALIDY project targets early treatment of metabolic liver diseases such as MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and ALD (Alcoholic Liver Disease), both of which are strongly linked to lifestyle factors like obesity and excessive alcohol consumption. These conditions, despite differing origins, exhibit similar early-stage liver lesions (MASH and sAH).
APPLICATIONS
The technology consists of either lactic acid bacterial (LAB) strains, aimed at restoring gut microbiota balance (correcting dysbiosis) and preventing progression of liver lesions in both MASLD and ALD at early stages.
ADVANTAGES
Preventive Approach: Focuses on early intervention, before the development of irreversible liver damage.
Patient-Derived Strains: LAB strains were naturally selected from individuals with high alcohol intake but no liver damage, suggesting strong protective potential.
Functional Benefits: Improve gut barrier function in vitro. Microbiota Transferability: Sensitivity to liver disease was transferable via microbiota, underscoring the causal role of specific bacteria and the relevance of the therapy.